One Year Follow-up from RSV F-Protein Vaccine Candidate Phase 1 Elderly Trial Demonstrates Sustained Levels of Immune Response

Sustained levels of RSV F antibody and palivizumab-competing antibody responses demonstrated over a 4 to 6 month period  Results support accelerating development plans for “seasonal” elderly RSV vaccine  Phase 2 clinical trial in elderly anticipated to start in late-2014/early-2015 May 12, 2014 Novavax, Inc. today announced follow-up data from its dose-ranging Phase 1 clinical trial of its respiratory syncytial virus (RSV) …